The U.S. FDA granted Resolution Bioscience Inc. breakthrough device designation for its cell-free DNA (cfDNA) assay, currently under development as a qualitative, in vitro companion diagnostic (CDx) to detect homologous recombination deficiency (HRD) mutations and gene deletions.
The U.S. FDA granted Resolution Bioscience Inc. breakthrough device designation for its cell-free DNA (cfDNA) assay, currently under development as a qualitative, in vitro companion diagnostic (CDx) to detect homologous recombination deficiency (HRD) mutations and gene deletions.
In the ongoing quest for more personalized and effective cancer treatments, Leverkusen, Germany-based Bayer AG is partnering with Roche Holding AG's Foundation Medicine Inc. (FMI) to develop genetic sequencing tests to identify patients who might benefit from various approved and investigational cancer therapies.
Endogastric Solutions Inc. (EGS), a Redmond, Wash.-based company developing an incisionless surgical technology to treat gastroesophageal reflex disease (GERD), raised $45 million in Series I financing, thanks to a late, $14.5 million shot in the arm from Israeli-based med-tech investment firm Accelmed Growth Partners.
